Skip to main content
2024 ISPE Annual Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Evaluation

Navigating the Cancer Landscape Using Innovative Pharmacoepidemiologic Methods

Tuesday, August 27, 2024
1:00 PM – 2:30 PM CEST
Location:Room II

Presentations:

  • 1:00 PM – 1:15 PM CEST
    Immune-Related Adverse Events of Anti-PD-(L)1 Immunotherapy With and Without Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Evidence Study

    Presenting Author: Ping Shao, M.B.B.S, MS – Regeneron

    Co-Author: Alexi N. Archambault, PhD, MPH – Regeneron

    Co-Author: Christian Hampp, PhD (he/him/his) – Regeneron Pharmaceuticals

    Co-Author: Rachel E. E. Sobel, DrPH (she/her/hers) – Regeneron

    Co-Author: Julius Asubonteng, PhD – Regeneron

    Co-Author: Gregory P. Geba, MD, DrPH – Regeneron Pharmaceuticals, Inc.

    Co-Author: Asha B. Pillai, MD – Regeneron

  • 1:15 PM – 1:30 PM CEST
    Developing a de-novo mortality model for relapsed and refractory multiple myeloma: emulation of subjective life expectancy criteria from a clinical trial in real-world data

    Co-Author: Alexander Breskin, PhD, MPH – Regeneron Pharmaceuticals

    Co-Author: Paul Spin – Eversana

    Co-Author: Di Wang – Eversana

    Co-Author: Qiufei Ma – Regeneron Pharmaceuticals

    Co-Author: Glenn S. Kroog – Regeneron Pharmaceuticals

    Presenting Author: Christian Hampp, PhD (he/him/his) – Regeneron Pharmaceuticals

  • 1:30 PM – 1:45 PM CEST
    The Comparative Risk of Urinary Tract Infections with Degarelix and Gonadotropin-Releasing Hormone Agonists among Patients Diagnosed with Prostate Cancer: A Population-Based Cohort Study

    Presenting Author: Farzin Khosrow-Khavar, PhD – Rutgers University

    Co-Author: Elisa Bandera, MD, PhD – Rutgers Cancer Institute of New Jersey

    Co-Author: Chintan Dave, PharmD, PhD – Rutgers University

  • 1:45 PM – 2:00 PM CEST
    Comparative effectiveness and cardiovascular safety of enzalutamide versus abiraterone amongst older U.S. men diagnosed with metastatic castration-resistant prostate cancer

    Presenting Author: Charles E. Gaber, PhD, MPH (he/him/his) – Department of Pharmacy Systems, Outcomes and Policy, University of Illinois Chicago, Chicago, IL, USA

    Co-Author: Ebere Okpara, BPharm – Department of Pharmacy Systems, Outcomes and Policy, University of Illinois-Chicago College of Pharmacy, Chicago, IL, USA

    Co-Author: Abdullah I. Abdelaziz, BPharm, MS – Department of Pharmacy Systems, Outcomes and Policy, University of Illinois-Chicago College of Pharmacy, Chicago, IL, USA

    Co-Author: Jyotirmoy Sarker, MPharm, MBA, MBiotech – University of Illinois Chicago, Department of Pharmacy Systems, Outcomes and Policy

    Co-Author: Kent A. Hanson, PharmD – Department of Pharmacy Systems, Outcomes and Policy, University of Illinois-Chicago College of Pharmacy, Chicago, IL, USA

    Co-Author: Lubna Hassan, PharmD – Department of Pharmacy Systems, Outcomes and Policy, University of Illinois-Chicago College of Pharmacy, Chicago, IL, USA

    Co-Author: Fang-Ju Lin, PhD, MS – 1 Department of Pharmacy Systems, Outcomes and Policy, University of Illinois-Chicago College of Pharmacy, Chicago, IL, USA

    Co-Author: Todd A. Lee, PharmD, PhD – Department of Pharmacy Systems, Outcomes and Policy, University of Illinois Chicago

    Co-Author: Natalie Reizine, MD – Division of Hematology & Oncology, Department of Medicine, University of Illinois-Chicago College of Medicine, Chicago, IL, USA

  • 2:00 PM – 2:15 PM CEST
    Incidence and Survival of Pregnancy Associated Breast Cancer: A Contribution from the IMI ConcePTION Project Piloted in Finland and Norway

    Presenting Author: Maarit K. Leinonen, MD, PhD – Knowledge Brokers, Finnish Institute for Health and Welfare; Teratology Information Service, Emergency Medicine and Services, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

    Co-Author: Visa Martikainen – Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland

    Co-Author: Cori Campbell, DPhil – Department of Data Science & Biostatistics, Julius Global Health, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands

    Co-Author: Saeed Hayati – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway

    Co-Author: Alexis Krumme, ScD – Johnson & Johnson, Titusville, New Jersey, USA

    Co-Author: Joan K. Morris – Population Health Research Institute, St George’s, University of London, UK

    Co-Author: Hedvig M.E Nordeng, PhD (she/her/hers) – Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, University of Oslo (UiO), Oslo, Norway

    Co-Author: Mika Gissler, PhD – Knowledge Brokers, Finnish Institute for Health and Welfare, Helsinki, Finland

  • 2:15 PM – 2:30 PM CEST
    Hypothetical target trial to compare the effectiveness of atezolizumab, pembrolizumab and nivolumab in second line treatment of advanced non-small cell lung cancer

    Presenting Author: Euloge Clovis Kenne Pagui, PhD – 1) Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo, Norway

    Co-Author: Simon Boge Brant – NordicRWE AS, Oslo, Norway

    Co-Author: Kristian Svendsen, PhD – NordicRWE AS, Oslo, Norway

    Co-Author: Arnoldo Frigessi – 1) Oslo Centre for Biostatistics and Epidemiology, Department of Biostatistics, University of Oslo

    Co-Author: Åslaug Helland – Division of Cancer Medicine, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo

    Co-Author: Steinar Ø Thoresen, MD PhD Professor emeritus – NordicRWE AS, Oslo, Norway

    Co-Author: Christian Jonasson – Norwegian University of Science and Technology